Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results $EDSA https://t.co/wARb8cY39M
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update $SRZN https://t.co/lLtCQWML0S
$ONCY - Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep https://t.co/xh2QsEtq00
Symbotic Inc. reported its third quarter fiscal year 2025 earnings with revenue reaching $592.1 million, surpassing estimates of approximately $533.9 million and marking a 20% year-over-year increase. The company's adjusted EBITDA was $45.4 million, also exceeding expectations of $29.1 million. However, Symbotic posted a loss per share of $0.05, wider than the estimated loss of $0.017 per share, and reported a net loss of $32 million. Cash and equivalents stood at $777.6 million, below the anticipated $1 billion. For the fourth quarter of fiscal 2025, Symbotic provided revenue guidance between $590 million and $610 million, which fell short of the estimated $634.4 million. The company indicated that a new storage structure implementation is expected to temporarily impact Q4 revenue. Following the earnings release and guidance, Symbotic's stock price declined by approximately 13%. In related earnings reports, Embecta Corp. announced third quarter fiscal 2025 results with revenue of $295.5 million, an 8.4% year-over-year increase, and adjusted EPS of $1.12, alongside a net income of $45.5 million. Surmodics also reported its third quarter fiscal 2025 financial results and updated its full-year guidance.
